"The early results showed dose-dependent muscle exposure, early biomarker effects, and favorable tolerability across both studies, with no dose-limiting toxicity observed to date."
"After a single dose, both programs demonstrated proof-of-concept data supporting reduction of the target protein or mRNA. The majority of adverse events were mild to moderate and were not dose dependent."
"Sarepta uses an αvβ6 integrin-targeted siRNA approach, which means the therapy is designed to lock onto a specific protein found on the surface of muscle cells."
Sarepta Therapeutics experienced a 20% stock increase following the release of its first clinical data from two siRNA programs aimed at rare neuromuscular diseases. The Phase 1/2 study results for SRP-1001 and SRP-1003 showed dose-dependent muscle exposure and favorable tolerability, with no dose-limiting toxicity. Approximately 16,000 individuals in the U.S. have facioscapulohumeral muscular dystrophy type 1, while around 40,000 have myotonic dystrophy type 1, both lacking approved treatments. The delivery mechanism utilizes an αvβ6 integrin-targeted siRNA approach for direct delivery to muscle cells.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]